[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627112":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":57,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Armed Forces Institute of Cardiology, Pakistan","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A patients who will be prescribed 2.5 mg of vericiguat along with standard treatment","EXPERIMENTAL","Sixty Five patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history will be noted. patients will be prescribed 2.5 mg of vericiguat. Dose will be increased to 5 mg and ultimately to the target dose of 10 mg once daily, as guided by evaluation of blood pressure and clinical symptoms along with standard treatment (sacubitril-valsartan).All patients will be followed-up in OPD for 3 months. During follow-up, patients will be examined for admission to the hospital for deterioration of heart condition or mortality due to cardiac event and side effects (as per operational definition). All the data will be recorded in Performa.",[13,14],"Drug: Vericiguat tablet","Drug: Sacubitril \u002F Valsartan",{"label":16,"type":17,"description":18,"interventionNames":19},"Group B patients who will be prescribed standard treatment only (sacubitril-valsartan)","ACTIVE_COMPARATOR","Sixty Five patients fulfilling the inclusion criteria will be enrolled from emergency department randomly. Informed consent will be taken from attendants. A detailed history will be noted. Patients will be prescribed standard treatment only (sacubitril-valsartan). All patients will be followed-up in OPD for 3 months. During follow-up, patients will be examined for admission to the hospital for deterioration of heart condition or mortality due to cardiac event and side effects (as per operational definition). All the data will be recorded in Performa.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Vericiguat tablet","Group A, patients will be prescribed 2.5 mg of vericiguat. Dose will be increased to 5 mg and ultimately to the target dose of 10 mg once daily, as guided by evaluation of blood pressure and clinical symptoms along with standard treatment (sacubitril-valsartan)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sacubitril \u002F Valsartan","Group A Patients it will be prescribed along with vericiguat but group B patients will have (sacubitril-valsartan) as standard treatment",[9,16],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Dr Khawaja Danish Ali, MBBS","CONTACT","+923448890893","khawajadanishali@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Armed Forces Institute of Cardiology. Pakistan","RECRUITING","Rawalpindi","Punjab Province","46000","Pakistan","PK",{"type":47,"coordinates":48},"Point",[49,50],73.0479,33.59733,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":26,"email":56},"Prof Dr Muhammad Nadir Khan, MBBS, FCPS","+923219156153","yesnadirkhan@gmail.com",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Khawaja Danish Ali","Principal Investigator","100627112","phase-1-vericiguat-in-decompensated-cardiac-failure-clinical-insights-on-addition-to-guidelines-derived-medical-therapy-vercig-trial-100627112",false,"NCT07444398","Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial","Inclusion Criteria:\n\n* Patients diagnosed with decompensated heart failure (patients with left ventricular ejection fraction ≤45% presenting with NYHA functional class III-IV symptoms or worsening class II symptoms. Along with elevated natriuretic peptide levels defined as NT-proBNP \\>1000 pg\u002FmL in patients with sinus rhythm and \\>1600 pg\u002FmL in patients with atrial fibrillation in the absence of alternative causes of biomarker elevation)\n\nExclusion Criteria:\n\n* Patients with blood pressure \\\u003C100 mmHg;\n* concurrent or anticipated use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors\n* use of intravenous inotropes or implantable left ventricular assist devices (on medical record)","ALL","25 Years","65 Years",{"count":71,"type":72},130,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","This study will compare the outcomes of Vericuguat and placebo in patient with decompensated heart failure . This study will carry out after approval from IERB. Seventy patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history including name, age, gender, duration of heart failure, history of alcoholism, smoking, diabetes, hypertension, EF at baseline and NYHA class will be noted. Patients will be randomly divided in two groups by using lottery method. Outcomes will be assessed at in terms of hospitalization for heart failure, death from cardiovascular event and side effects.",[78],"Decompensated Heart Failure",[80,81,82],"Vericuguat","Heart failure","Emergency Department","2026-02-26",{"date":85,"type":86},"2026-03-02","ACTUAL",{"date":88,"type":86},"2026-01-01",{"date":90,"type":72},"2026-03-31",{"name":59,"class":6},1]